Anti–vascular endothelial growth factor therapy for age-related macular degeneration: systematic review and network meta-analysis
[sidebar]
Commissioned and Funded by: Canadian Institutes of Health Research (CIHR) through the Drug Safety and Effectiveness Network (DSEN)
- Our results can be used by patients and their healthcare providers, as well as policy-makers to guide decision-making regarding use of the anti-VEGF agents
- Anti-VEGF agents are effective for improving vision gain, mean BCVA, and reducing vision loss for patients with wet AMD
- Compared to placebo, we did not observe an association between their use and increased adverse events or mortality
Related Projects:
[/sidebar-content]Category : KS Projects
Date : 11 Aug 2020